Multiple Sclerosis: Looking Toward the Future

July 24, 2024

Ryan Haumschild, PharmD, MS, MBA
Heidi Crayton, MD

Opinion

Video

Heidi Crayton, MD, and Maria Lopes, MD, discuss future research in multiple sclerosis that they find exciting and promising.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

Now Viewing

EP: 13.Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following question:

Are there any areas of future research in multiple sclerosis (MS) that you are excited for?

Related Content

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Article

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Millennials With Multiple Sclerosis: Are They Different or Has Medicine Evolved?

November 30th 2021

Podcast

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

Listen

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Pain May Be Indicator of MS Prior to Disease Onset: Study

January 6th 2025

Article

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.

Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News

December 1st 2019

Podcast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Listen